Relay Therapeutics (RLAY) Competitors $3.34 -0.15 (-4.30%) Closing price 04:00 PM EasternExtended Trading$3.48 +0.15 (+4.34%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RLAY vs. NAMS, BLTE, HRMY, KNSA, VCEL, DNLI, CGON, VERA, GMTX, and IMCRShould you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include NewAmsterdam Pharma (NAMS), Belite Bio (BLTE), Harmony Biosciences (HRMY), Kiniksa Pharmaceuticals (KNSA), Vericel (VCEL), Denali Therapeutics (DNLI), CG Oncology (CGON), Vera Therapeutics (VERA), Gemini Therapeutics (GMTX), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry. Relay Therapeutics vs. Its Competitors NewAmsterdam Pharma Belite Bio Harmony Biosciences Kiniksa Pharmaceuticals Vericel Denali Therapeutics CG Oncology Vera Therapeutics Gemini Therapeutics Immunocore NewAmsterdam Pharma (NASDAQ:NAMS) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, community ranking, valuation and institutional ownership. Does the media refer more to NAMS or RLAY? In the previous week, NewAmsterdam Pharma had 24 more articles in the media than Relay Therapeutics. MarketBeat recorded 30 mentions for NewAmsterdam Pharma and 6 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.76 beat NewAmsterdam Pharma's score of 0.57 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 10 Very Positive mention(s) 1 Positive mention(s) 13 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend NAMS or RLAY? NewAmsterdam Pharma currently has a consensus price target of $43.00, suggesting a potential upside of 109.76%. Relay Therapeutics has a consensus price target of $17.67, suggesting a potential upside of 428.94%. Given Relay Therapeutics' higher possible upside, analysts plainly believe Relay Therapeutics is more favorable than NewAmsterdam Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Relay Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.83 Is NAMS or RLAY more profitable? NewAmsterdam Pharma's return on equity of 0.00% beat Relay Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam PharmaN/A N/A N/A Relay Therapeutics N/A -45.75%-40.75% Does the MarketBeat Community believe in NAMS or RLAY? Relay Therapeutics received 33 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 90.91% of users gave NewAmsterdam Pharma an outperform vote while only 70.00% of users gave Relay Therapeutics an outperform vote. CompanyUnderperformOutperformNewAmsterdam PharmaOutperform Votes3090.91% Underperform Votes39.09%Relay TherapeuticsOutperform Votes6370.00% Underperform Votes2730.00% Which has more risk and volatility, NAMS or RLAY? NewAmsterdam Pharma has a beta of -0.03, meaning that its stock price is 103% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Which has better valuation & earnings, NAMS or RLAY? NewAmsterdam Pharma has higher revenue and earnings than Relay Therapeutics. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$47.14M48.82-$176.94M-$1.88-10.90Relay Therapeutics$7.68M74.57-$341.97M-$2.23-1.50 Do insiders & institutionals believe in NAMS or RLAY? 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 20.8% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 4.9% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryNewAmsterdam Pharma beats Relay Therapeutics on 9 of the 17 factors compared between the two stocks. Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLAY vs. The Competition Export to ExcelMetricRelay TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$572.63M$3.09B$5.57B$8.61BDividend YieldN/A1.58%5.28%4.18%P/E Ratio-1.2833.3227.1720.06Price / Sales74.57469.84409.72157.10Price / CashN/A168.6838.2534.64Price / Book0.573.457.064.70Net Income-$341.97M-$72.35M$3.23B$247.88M7 Day Performance3.41%6.16%2.68%2.20%1 Month Performance10.96%20.42%12.02%9.44%1 Year Performance-53.80%-17.03%31.24%14.72% Relay Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLAYRelay Therapeutics2.3967 of 5 stars$3.34-4.3%$17.67+428.9%-53.7%$572.63M$7.68M-1.28330NAMSNewAmsterdam Pharma2.97 of 5 stars$18.93+4.5%$43.00+127.2%+11.0%$2.13B$47.14M-10.074Trending NewsAnalyst ForecastAnalyst RevisionBLTEBelite Bio2.265 of 5 stars$65.02+0.2%$96.67+48.7%+24.8%$2.07BN/A-58.5810Short Interest ↑Analyst RevisionHRMYHarmony Biosciences4.7728 of 5 stars$35.56+3.1%$53.00+49.0%+19.8%$2.04B$744.85M16.85200Positive NewsShort Interest ↑Analyst RevisionKNSAKiniksa Pharmaceuticals3.2856 of 5 stars$27.92+2.0%$38.80+39.0%+54.9%$2.04B$481.17M-199.41220Trending NewsInsider TradeVCELVericel2.6568 of 5 stars$40.46-2.0%$61.14+51.1%+5.0%$2.04B$238.54M674.45300News CoveragePositive NewsHigh Trading VolumeDNLIDenali Therapeutics4.3464 of 5 stars$13.96+5.4%$33.71+141.5%-27.4%$2.03B$330.53M-5.06430Positive NewsAnalyst RevisionHigh Trading VolumeCGONCG Oncology2.4702 of 5 stars$26.59+3.8%$58.22+119.0%-22.0%$2.03B$662K-17.6161Positive NewsAnalyst RevisionVERAVera Therapeutics2.8356 of 5 stars$31.74+67.5%$65.00+104.8%-42.0%$2.02BN/A-12.1640Short Interest ↑Analyst RevisionGap UpHigh Trading VolumeGMTXGemini TherapeuticsN/A$46.68-0.4%N/A+31.4%$2.02BN/A-46.6830High Trading VolumeIMCRImmunocore2.9124 of 5 stars$38.65+5.6%$58.89+52.4%-11.2%$1.94B$333.58M-40.68320Positive NewsAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies NAMS Alternatives BLTE Alternatives HRMY Alternatives KNSA Alternatives VCEL Alternatives DNLI Alternatives CGON Alternatives VERA Alternatives GMTX Alternatives IMCR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLAY) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
